England seeks views on including men in HPV vaccine programme
This article was originally published in Scrip
Just as the UK's NHS prepares to switch from GlaxoSmithKline's human papillomavirus vaccine Cervarix to Sanofi Pasteur MSD's Gardasil, England's Joint Committee on Vaccination and Immunisation has put out a call for evidence on whether it should amend its HPV immunisation programme to include men. It will be considering how some men might benefit from vaccination and the potential impact of higher valency vaccines.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.